Roberto Bertini
Vita-Salute San Raffaele University
CancerInternal medicineRadiologyUrologySurgeryOncologyRenal functionRenal cell carcinomaCarcinomaKidney diseaseProstatectomyProstate cancerNephrectomyLymph nodeKidney cancerNephron sparing surgeryIn patientProportional hazards modelGeneral surgeryMedicine
332Publications
31H-index
3,246Citations
Publications 338
Newest
#1Andrea Mari (UniFI: University of Florence)H-Index: 31
#2Riccardo Tellini (UniFI: University of Florence)H-Index: 9
Last. Enrico Checcucci (UNITO: University of Turin)H-Index: 21
view all 22 authors...
Abstract null null Background null Robot-assisted partial nephrectomy (RAPN) is increasingly adopted for the treatment of localized renal tumors; however, rates and predictors of significant renal function (RF) loss after RAPN are still poorly investigated, especially at a long-term evaluation. null null null Objective null To analyze the predictive factors and develop a clinical nomogram for predicting the likelihood of ultimate RF loss after RAPN. null null null Design, setting, and participan...
Source
#1G. BasileH-Index: 2
#2Giuseppe RosielloH-Index: 9
view all 21 authors...
Source
Source
#1Giuseppe FallaraH-Index: 3
#2Marco BandiniH-Index: 24
Last. Zhe TianH-Index: 30
view all 18 authors...
Source
#1Alberto MartiniH-Index: 27
#2Giuseppe FallaraH-Index: 3
Last. Alberto BrigantiH-Index: 96
view all 16 authors...
Source
#1G. BasileH-Index: 2
#2Giuseppe RosielloH-Index: 9
view all 19 authors...
Source
#1Carlo Andrea Bravi (UniSR: Vita-Salute San Raffaele University)H-Index: 10
#2Andrea Mari (UniFI: University of Florence)H-Index: 31
Last. Andrea Minervini (UniFI: University of Florence)H-Index: 37
view all 31 authors...
Abstract Background Ischemia time during partial nephrectomy (PN) is among the greatest determinants of acute kidney injury (AKI). Whether this association is affected by the preoperative risk of AKI has never been investigated. Objective To assess the effect of the interaction between the preoperative risk of AKI and ischemia time on the probability of AKI during PN. Design, setting, and participants Data of 944 patients treated with on-clamp PN for cT1 renal tumors were extracted from the Regi...
1 CitationsSource
#1Federico Di MarcoH-Index: 3
#2Antonello Pani (University of Cagliari)H-Index: 27
Last. Roberto BertiniH-Index: 31
view all 14 authors...
Acute kidney injury (AKI) and chronic kidney disease (CKD) are common events after radical nephrectomy (RN). In this study we aimed to predict AKI and CKD after RN relying on specific histological aspects. We collected data from a cohort of 144 patients who underwent radical nephrectomy. A histopathological review of the healthy part of the removed kidney was performed using an established chronicity score (CS). Logistic regression analyses were performed to predict AKI after RN, while linear re...
Source
#1Giuseppe Rosiello (UniSR: Vita-Salute San Raffaele University)H-Index: 9
#2Alessandro Larcher (UniSR: Vita-Salute San Raffaele University)H-Index: 29
Last. Umberto Capitanio (UniSR: Vita-Salute San Raffaele University)H-Index: 62
view all 14 authors...
PURPOSE The current literature regarding the effect of blood loss (eBL) after nephron-sparing surgery (NSS) on long-term renal function is scarce. We tested the effect of eBL on the risk of developing chronic kidney disease (CKD) after NSS. METHODS Within an institutional prospectively maintained database, we identified 215 patients treated with NSS for cT1N0M0 renal mass at one European high-volume center. Multivariable logistic regression models tested the effect of eBL on the risk of developi...
3 CitationsSource
#1Giuseppe Fallara (UniSR: Vita-Salute San Raffaele University)H-Index: 3
#2Marco Bandini (UniSR: Vita-Salute San Raffaele University)H-Index: 24
Last. Roberto Bertini (UniSR: Vita-Salute San Raffaele University)H-Index: 31
view all 13 authors...
The indications for adjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) agents after curative intent nephrectomy for renal cell carcinoma are still a matter of debate. The ASSURE, PROTECT and ATLAS trials have failed to meet their primary end-points. Conversely, S-TRAC has shown a disease free survival (DFS) benefit. To date, meta-analyses have repeatedly proved the absence of a clinical benefit, in term of DFS and overall survival (OS). Nevertheless, the results of ...
Source